Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARKLE: 177Lu-PSMA-617 in Low-Volume Metastatic Hormone-Sensitive Prostate Cancer
NCT07650240Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Mayo Clinic. Started Aug 2026; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07650240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650240.